Maybank IB advises investors to look at Genting given its involvement in life sciences
KUALA LUMPUR: Maybank Investment Bank (Maybank IB) is advising investors to explore opportunities in Genting Bhd's involvement in the life sciences sector via TauRx Pharmaceuticals Ltd.
This recommendation precedes TauRx Pharmaceuticals' unveiling of complete findings from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM), aimed at tackling Alzheimer's disease, scheduled for March 7.
"The company has started discussions with regulators in the UK and the US for product approval.
"In an optimistic scenario where the product is approved and TauRx is valued at US$15 billion with no discount, the target price for Genting could increase to RM9.40.
"Our estimates and RM5.73 target price remain the same, but we advise investors to buy now to position themselves early," it said.
However, TauRx claims that HMTM is effective in slowing cognitive decline and reducing brain atrophy, is safe without causing brain bleeding, and will be more affordable if approved because it can be taken orally instead of intravenously.
The life sciences company will present the 24-month data from its Phase 3 LUCIDITY trial of HMTM at the AD/PD 2024 Alzheimer's and Parkinson's Diseases Conference on March 7 in Lisbon, Portugal.
This presentation will include details of the final 12-month open-label phase of the trial, following the initial results reported throughout 2022.
Target price for Genting could increase to RM9.40.
On March 12, 2024 the FDA updated early Alzheimer’s drug development guidance to add support for biomarkers, surrogate endpoints. Timely development for TauRx.
Background
FDA is announcing the availability of a revised draft guidance for industry entitled “Early Alzheimer's Disease: Developing Drugs for Treatment.” This draft guidance is intended to assist sponsors in the clinical development of drugs for the treatment of the stages of sporadic AD that occur before the onset of overt dementia. This draft guidance revises the draft guidance for industry entitled “Early Alzheimer's Disease: Developing Drugs for Treatment” issued February 16, 2018 (83 FR 7060), and reflects FDA's consideration of public comments on the draft guidance. This revision describes FDA's current thinking regarding the use of biomarkers for the selection of participants with early stages of AD for enrollment in clinical trials, the selection of outcome measures for clinical trials in early AD, and the use of effects on characteristic pathophysiological changes of AD to support approval in these populations.
A general section on outcome measures has been changed in the latest revision, now incorporating descriptions surrounding the use of co-primary endpoints and cognition originally found in the background section the 2018 draft guidance. The outcome measures section contains subsections describing clinical endpoints, time-to-event analysis, and surrogate endpoints.
“Sponsors considering the use of a biomarker as the primary measure of effect should discuss their plans with FDA early in development,” FDA wrote. “In general, even if accelerated approval is considered as the initial approval pathway, clinical outcome assessments should be included in clinical trials for early AD to assess early clinical changes that may potentially provide support for any changes observed on biomarkers.”
Taufix aproval take 6 month proceed , Genting pi 4.50 to 4.60 go in buy n kept until QR May , QR May sure good , TP 5.40 after QR May announed , net profit guarantee increase , 2024 Feb , 1 month cuti + Chinese New Year cukup bring higher net profit , will reflect at QR MAY TP 5.40 after QR May
I am confident we will hear about regulatory approval of TauRx by August / September 2024. So worth remain invested in 2024….meanwhile take the dividends a they come. Not convinced about Genting business strategy though …willing to pay high taxes …….not many foreign companies make money in US particularly old business like gambling ….for boss it is ok as he can make money other way by dealing in shares and TP transactions etc
Prices fluctuate.. up & down, up and down.., will they drop when investors leave in May? We know one thing is certain: Genting's next quarterly report should be promising
How many people are in NYC in a day? As of 2021, the population of New York City was estimated to be around 8.8 million people. This figure represents the residents of the city and does not account for daily fluctuations due to tourists, commuters, and other temporary visitors. Keep in mind that this number may have changed slightly since then.
How many tourists visit New York state each year? New York State also saw a 10% bump in visitation, with 291.5 million travelers compared to 266.7 million visitors in 2019. The year-over-year increases from 2021 to 2022 were overwhelming, with a 22% increase in visitation, over 50% gain in spending, and a more than 43% jump in economic impact. 13 Sept 2023
LKT is a veteran n shrewd biz man. I think overall he is ok as CEO, just that he will milk more for himself along the way (self interest first, its human nature la). ATK is just a hopeless punter that gambled showhand for Taurx investment luckily it turned out well 🙏
Taurx could be a longer haul game, all depending on the corrupted FDA's decision on next yr Q3. Meanwhile those rights shares i bought has been compounding at over 100% annually over the last 2.5yrs. Im confident this compounding rate can continue on for another yr with UAE CA in Q4 this yr + deals waiting at sideline being activated after the first CA.
Sold for 4.94 a few weeks ago...then next day it close at 5.05 i think. was kicking myself but not so much now 😅. But i did sell it before the ex-date so basically 4.85.
How do judge CEO’s performance? Business sales, profitability or share price growth and total returns to shareholders? Genting has been performing very poorly since 2011 when share prices peaked. Since than it has drifted downwards …..so in my assessment CEO has not delivered …look at leading companies CEO they deliver share price growth or they are removed or resign.on top of this he is highest paid CEO by some distance. So I am afraid you cannot say he is ok and has done well? Based on what metrics, just favouritism.
Put it another way if you invested in 2011 you would not have made any money ….or should I say capital gain. That is a long period of under performance ….!
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
neohts
2,461 posts
Posted by neohts > 2024-04-08 10:19 | Report Abuse
https://www.nst.com.my/business/corporate/2024/03/1021303/maybank-ib-advises-investors-look-genting-given-its-involvement
Maybank IB advises investors to look at Genting given its involvement in life sciences
KUALA LUMPUR: Maybank Investment Bank (Maybank IB) is advising investors to explore opportunities in Genting Bhd's involvement in the life sciences sector via TauRx Pharmaceuticals Ltd.
This recommendation precedes TauRx Pharmaceuticals' unveiling of complete findings from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM), aimed at tackling Alzheimer's disease, scheduled for March 7.
"The company has started discussions with regulators in the UK and the US for product approval.
"In an optimistic scenario where the product is approved and TauRx is valued at US$15 billion with no discount, the target price for Genting could increase to RM9.40.
"Our estimates and RM5.73 target price remain the same, but we advise investors to buy now to position themselves early," it said.
However, TauRx claims that HMTM is effective in slowing cognitive decline and reducing brain atrophy, is safe without causing brain bleeding, and will be more affordable if approved because it can be taken orally instead of intravenously.
The life sciences company will present the 24-month data from its Phase 3 LUCIDITY trial of HMTM at the AD/PD 2024 Alzheimer's and Parkinson's Diseases Conference on March 7 in Lisbon, Portugal.
This presentation will include details of the final 12-month open-label phase of the trial, following the initial results reported throughout 2022.
Target price for Genting could increase to RM9.40.